A Tmod team|up for A2 Biotherapeutics and Merck

AGOURA HILLS, Calif., December 23, 2020 — A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer ...

A2 Biotherapeutics Enters into Collaboration Agreement With Merck

A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, announced that it has entered into an ...

A Tmod team-up for A2 Biotherapeutics and Merck

A Tmod team-up for A2 Biotherapeutics and Merck ... AGOURA HILLS, Calif. & KENILWORTH, N.J.—A2 Biotherapeutics disclosed today that the company ...

A2 Biotherapeutics Partnerships

A2 Bio has a research collaboration with Merck for its first allogeneic program and an option for a second program.

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck ...

PRNewswire/ -- A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients with ...

A2 Bio Publishes Key Preclinical Findings Demonstrating Tmod ...

... team with 90+ years combined experience in biotech and cell therapy ... Merck. For more information, please visit www.a2bio.com and ...

A2 Biotherapeutics Enters into Collaboration Agreement With MSD

... Merck & Co., Inc., Rahway, N.J., USA) in which A2 will continue research and preclinical development of its undisclosed Tmod ... Executive team · Culture ...

A2 Bio's activator-blocker CAR-T cell therapies show early promise ...

A2 Bio showed CAR-T cells built with its Tmod platform could selectively destroy solid tumors while sparing normal cells in mice.

About Us - A2 Biotherapeutics

The Tmod™ technology was invented by A2 Bio scientists, leveraging decades ... team of dedicated scientists and professional staff, A2 Bio is uniquely ...

News briefing: Merck buys into A2's T cell therapy platform

Merck is dipping its toes into a cell therapy partnership with A2 Biotherapeutics, with an offer to co-fund clinical development and ...

Newsroom - A2 Biotherapeutics

November 9, 2024. A2 Bio Highlights Progress of Tmod TM CAR T-Cell Clinical Programs during 2024 Annual Meeting of the Society for Immunotherapy of Cancer ...

A2 Biotherapeutics Starts 'Tmod' Drug Clinical Trials

In 2020, A2 Biotherapeutics established a research collaboration with Darmstadt, Germany-based pharma giant Merck & Co. Inc., which represented ...

A2 Bio's new CEO aims to grow platform

The firm invented the Tmod cell therapy platform to address the ... “I share with the A2 Bio team and board a deeply held, enduring ...

A2 Bio publishes key preclinical findings demonstrating potential of ...

A2 Biotherapeutics has invented the Tmod™ cell therapy platform to ... team with 90+ years combined experience in biotech and cell ...

Brown Rudnick Advises A2 Biotherapeutics in Collaboration ...

Brown Rudnick represented A2 Biotherapeutics in an agreement with Merck in which A2 ... The Firm played a major role on the deal team as IP ...

A2 Bio Preclinical Data Update for CEA and MSLN Programs at ...

The Tmod™ mechanism utilizes two receptors to exploit common ... team with 90+ years combined experience in biotech and cell therapy ...

Our Pipeline - A2 Biotherapeutics

UNDISCLOSED. COMMERCIAL RIGHTS. Merck. Discovery. IND-Enabling. Phase1 ... A2B530 is a Tmod™ chimeric antigen receptor (CAR) T cell therapy targeting ...

A2 Biotherapeutics, Inc. - LeadIQ

... A2 Biotherapeutics has strengthened its leadership team. Leveraging the ... A2 Biotherapeutics and Merck announced a collaboration in December 2020 to ...

A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation ...

The Tmod system exploits irreversible genetic changes in cancer ... team with 90+ years combined experience in biotech and cell therapy ...

A2 Bio's therapy gains orphan drug status for colorectal cancer

The designation is a significant milestone for A2B530, the first autologous logic-gated therapy developed from A2 Bio's Tmod platform. Go ...